Trial Profile
A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary)
- Indications Vaso-occlusive crisis
- Focus Therapeutic Use
- Acronyms HESTIA3
- Sponsors AstraZeneca
- 18 Jul 2022 Primary endpoint (Number of VOCs) has not been met according to the results published in the Blood
- 18 Jul 2022 Results assessing the efficacy and safety of the reversible P2Y12 inhibitor ticagrelor versus placebo in preventing vaso-occlusive crises in pediatric patients with sickle cell disease published in the Blood
- 24 Dec 2021 This trial has been completed in Belgium (End date - 2020-08-13), according to European Clinical Trials Database record.